New Treatments for Hidradenitis Suppurativa (HS) in Major Markets
Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful lumps and abscesses, often in areas like the armpits […]
Hidradenitis suppurativa (HS) is a chronic skin condition that causes painful lumps and abscesses, often in areas like the armpits […]
The U.S. Food and Drug Administration (FDA) has appointed Dr. George Tidmarsh as the new director of its Center for
Artificial intelligence (AI) is changing how healthcare and drug companies use real-world patient data. But simply using AI isn’t enough—it
Bristol Myers Squibb has named Dr. Cristian Massacesi as its new Executive Vice President and Chief Medical Officer, overseeing all
A new report predicts that the market for hidradenitis suppurativa (HS) treatments will grow significantly over the next decade, from
European drug regulators have recommended rejecting Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), in a setback for its
During Jazz Pharmaceuticals’ fourth-quarter earnings call, CEO Bruce Cozadd quickly highlighted the company’s interest in making new deals. Some of the drugs they are known for include Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia.
The text is written by Brad Chapman, who is the Head of U.S. Epilepsy and Rare Syndromes at UCB. It discusses epilepsy and mentions some medications used for treatment, such as Keppra, Briviact, and Vimpat. The aim is to improve understanding of epilepsy and how these medications can help manage the condition.
In recent years, Eli Lilly has announced a number of increasingly large manufacturing investments. This has led many to wonder what the company will do next. Some of their well-known medications include Trulicity, Jardiance, and Cymbalta.
Organovo’s main drug, FXR314, is going to be tested in a Phase II trial for treating inflammatory bowel disease (IBD). Some common medications for IBD include Mesalamine (Asacol, Pentasa) and Infliximab (Remicade), but FXR314 is being studied to see if it could be a new option.